Roots Analysis

OCTOBER 13, 2023

Over the last two decades the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to more enhanced, potent, and targeted therapeutics. This led the researchers to find alternative pathways and drug delivery strategies to enhance the potent delivery of the drug to the site of action.

Drugs 40

Drugs Antibody RNA Genetics 40

Roots Analysis

MARCH 13, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry.

Manufacturing 52

Manufacturing Drug Delivery Marketing Drug Delivery Systems 52

Roots Analysis

AUGUST 8, 2023

Furthermore, a wide variety of drugs and macromolecules, including DNA , proteins, and imaging agents, can be encapsulated in liposomal vesicles due to their unique ability to entrap both lipophilic and hydrophilic substances. The various therapeutic applications of liposomes in drug delivery have been highlighted in the figure.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs In-Vivo 52

The Pharma Data

APRIL 8, 2021

Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D, said: “Our data at AACR reflect a robust early-stage pipeline, poised to deliver life-changing medicines to patients living with cancer. Data identifying a novel immunosuppressive myeloid gene signature for clinical biomarker development.

DNA 52

DNA Medicine Genome Genomics 52

Roots Analysis

MARCH 9, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. Concluding Remarks.

Manufacturing 52

Manufacturing Marketing Contract Manufacturing Protein 52

Delveinsight

NOVEMBER 29, 2020

Therapies such as dexamethasone drug delivery system and vascular endothelial growth factor inhibitors have already pierced deeper into the market. Brolucizumab is a humanized single-chain antibody fragment (scFv).

Marketing 52

Marketing Pharma Companies Drug Delivery Clinical Trials 52

The Pharma Data

MAY 15, 2023

Roche’s Chief Medical Officer and Head of Global Product Development. “If If approved, this would be the third indication for Vabysmo, the first bispecific antibody available for the treatment of retinal conditions that can cause blindness.” 7 About Vabysmo® (faricimab) Vabysmo is the first bispecific antibody approved for the eye.

Antibody 40

Antibody In-Vitro Clinical Development Medicine 40

Drug Discovery World

AUGUST 3, 2022

Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake. Over the years, a range of different CPPs have been developed, including natural translocating proteins through to newly-designed computer-prediction sequences 3.

Bioavailability 52

Bioavailability In-Vivo RNA In-Vitro 52

The Pharma Data

APRIL 12, 2023

4-7 Additionally, phase I data for an investigational anti-interleukin-6 (IL-6) treatment in uveitic macular edema (UME), to be presented for the first time, suggest the monoclonal antibody may improve visual acuity in patients with UME. Chief Medical Officer and Head of Global Product Development. “We

Antibody 40

Antibody In-Vitro Development Trials 40

The Pharma Data

JUNE 26, 2021

Roche’s Chief Medical Officer and Head of Global Product Development. “If Roche has a robust phase III clinical development programme underway for PDS, including the Portal, Pagoda and Pavilion studies. 11,12 It develops when new and abnormal blood vessels grow uncontrolled under the macula, causing swelling, bleeding and/or fibrosis.

Drug Delivery 52

Drug Delivery Clinical Trials Clinical Trials Medicine 52

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

JANUARY 17, 2024

Our aim is to accelerate progression from deep mechanistic human biology to biotech-enabled drug development.” “We are combining and building on the best practices from universities, institutes, and venture capital firms to create a new model that will speed the development of life-saving medicines for patients. .

Drugs 52

Drugs Drug Delivery Life Science Gene 52

Roots Analysis

MARCH 24, 2022

Genomics is the study of genetic material within a cell, and transcriptomics is the study of gene activity in different cells. Personalized medicine or precision medicine is an emerging field with the potential to develop novel and efficacious custom-based clinical therapies, wherein metabolomics holds a potential role. Web: [link].

Clinical Research 52

Clinical Research Development Research Drug Delivery Systems 52

Drug Discovery World

APRIL 29, 2024

He holds a PhD in Chemistry for early work on antibody drug conjugates in 1987 and was awarded the Bioprocessing Lifetime Achievement Award in 2021. Hall has been with the company for more than 16 years, including as Chief Commercial Officer, and was previously Head of Business Development in Europe for Cyprotex.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

Roots Analysis

OCTOBER 22, 2023

Coding RNAs include messenger RNA (mRNA) and short interfering RNA (siRNA), which encode proteins and silence gene expression, respectively. In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. RNA therapeutics offer several advantages over small molecules.

RNA 40

RNA Protein Genetics Gene Expression 40

The Pharma Data

JANUARY 17, 2021

a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced dose administration for the first patient in a Phase 2a clinical study of the company’s lead drug candidate, STP705, for the treatment of cutaneous basal cell carcinoma. GAITHERSBURG, Md.

Gene Expression 52

Gene Expression Trials Production Development 52

Pharmaceutical Technology

APRIL 24, 2023

In 1974, Dr. Robert Langer was part of the first cohort of researchers to begin nanoparticle research , as his lab at Cornell University developed tiny particles to deliver large molecules for angiogenesis. The next wave came from early research into liposomes and lipid nanoparticles, both of which are used for drug delivery.

Drug Delivery 147

Drug Delivery Vaccination Vaccine Research 147